313 related articles for article (PubMed ID: 24299497)
1. The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.
Henderson EJ; Lord SR; Close JC; Lawrence AD; Whone A; Ben-Shlomo Y
BMC Neurol; 2013 Dec; 13():188. PubMed ID: 24299497
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.
Neumann S; Taylor J; Bamford A; Metcalfe C; Gaunt DM; Whone A; Steeds D; Emmett SR; Hollingworth W; Ben-Shlomo Y; Henderson EJ
BMC Neurol; 2021 Oct; 21(1):422. PubMed ID: 34715821
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
Henderson EJ; Lord SR; Brodie MA; Gaunt DM; Lawrence AD; Close JC; Whone AL; Ben-Shlomo Y
Lancet Neurol; 2016 Mar; 15(3):249-58. PubMed ID: 26795874
[TBL] [Abstract][Full Text] [Related]
4. Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT.
Ashburn A; Pickering R; McIntosh E; Hulbert S; Rochester L; Roberts HC; Nieuwboer A; Kunkel D; Goodwin VA; Lamb SE; Ballinger C; Seymour KC
Health Technol Assess; 2019 Jul; 23(36):1-150. PubMed ID: 31339100
[TBL] [Abstract][Full Text] [Related]
5. [Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling].
Amadori K
Z Gerontol Geriatr; 2016 Oct; 49(7):662-663. PubMed ID: 27599816
[No Abstract] [Full Text] [Related]
6. Rivastigmine: in Parkinson's disease dementia.
Siddiqui MA; Wagstaff AJ
CNS Drugs; 2006; 20(9):739-47; discussion 748-50. PubMed ID: 16953649
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
[TBL] [Abstract][Full Text] [Related]
8. Cholinesterase inhibitors for Parkinson's disease dementia.
Maidment I; Fox C; Boustani M
Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
[TBL] [Abstract][Full Text] [Related]
9. Effect of augmenting cholinergic function on gait and balance.
Mancini M; Fling BW; Gendreau A; Lapidus J; Horak FB; Chung K; Nutt JG
BMC Neurol; 2015 Dec; 15():264. PubMed ID: 26697847
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up.
van Mierlo TJM; Foncke EMJ; Post B; Schmand BA; Bloem BR; van Harten B; Tissingh G; Munts AG; de Haan RJ; de Bie RMA;
Brain Behav; 2021 Aug; 11(8):e2257. PubMed ID: 34291590
[TBL] [Abstract][Full Text] [Related]
11. Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients.
Li Z; Yu Z; Zhang J; Wang J; Sun C; Wang P; Zhang J
Eur Neurol; 2015; 74(1-2):86-91. PubMed ID: 26288230
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
Wesnes K
Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
[TBL] [Abstract][Full Text] [Related]
13. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
Reilly S; Dhaliwal S; Arshad U; Macerollo A; Husain N; Costa AD
Eur J Neurol; 2024 Feb; 31(2):e16142. PubMed ID: 37975761
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
15. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
16. Lisbon Intensive Falls Trampoline Training (LIFTT) Program for people with Parkinson's for balance, gait, and falls: study protocol for a randomized controlled trial.
Domingos J; Dean J; Fernandes JB; Ramos C; Grunho M; Proença L; Vaz JR; Godinho C
Trials; 2023 Feb; 24(1):101. PubMed ID: 36755331
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Weintraub D; Somogyi M; Meng X
Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
[TBL] [Abstract][Full Text] [Related]
18. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial.
Montero-Odasso M; Wells JL; Borrie MJ; Speechley M
BMC Neurol; 2009 Aug; 9():42. PubMed ID: 19674471
[TBL] [Abstract][Full Text] [Related]
19. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
[TBL] [Abstract][Full Text] [Related]
20. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
